Table 2 Clinicopathological features of all pigmented hepatocellular neoplasms
From: Pigmented hepatocellular adenomas have a high risk of atypia and malignancy
Case | Classification of hepatocellular neoplasm | Age, gender | Number of lesions in patient | Size (cm) a | Cytological atypia | Architectual atypia | Reticulin | Pigment score b | Phenotype |
|---|---|---|---|---|---|---|---|---|---|
1 | Adenoma | 34, F | 1 | 11 | No | No | Intact | 2 | HNF1-α inactivated |
2 | Adenoma | 35, F | 1 | 5.2 | No | No | Intact | 1 | Inflammatory+β-catenin activated |
3 | Adenoma | 24, F | 1 | 11.5 | No | No | Intact (focal fat associated reduction) | 3 | HNF1-α inactivated |
4 | Adenoma | 58, F | 1 | 12 | No | No | Intact | 3 | HNF1-α inactivated |
5 | Adenoma | 35, F | 1 | Unavailable, biopsy specimen | No | No | Intact | 2 | HNF1-α inactivated+β-catenin activated |
6 | Adenoma | 36, F | >50 | 4.5 | No | No | Intact (focal fat associated reduction) | 1 | HNF1-α inactivated |
7 | Adenoma | 40, F | 2 | 7.7 | No | No | Intact | 1 | Inflammatory |
8 | Adenoma | 57, F | 2 | 2.9 | No | No | Intact | 1 | HNF1-α inactivated |
9 | Adenoma | 47, F | 2 | 6 | No | No | Intact | 3 | HNF1-α inactivated |
10 | Adenoma | 27, F | 2 | 15 | No | No | Intact (focal fat associated reduction) | 1 | HNF1-α inactivated |
11 | Adenoma | 31, F | 2 | 2.4 | No | No | Intact | 1 | HNF1-α inactivated |
12 | Carcinoma arising in adenoma | 34, F | 1 | 10 | Yes | Yes | Patchy loss | 2 | Unclassified |
13 | Carcinoma arising in adenoma | 55, F | 1 | 2.4 | Yes | Yes | Loss | 1 | β-catenin activated |
14 | Carcinoma arising in adenoma | 18, F | 1 | 1.5 | No | Yes | Patchy loss | 1 | HNF1-α inactivated |
15 | Carcinoma arising in adenoma | 20, M | 1 | 10 | Yes | No | Loss | 1 | Inflammatory |
16 | Carcinoma | 37, M | 4 (including 3 non-pigmented adenomas) | 3.7 | No | Yes | Patchy loss | 1 | β-catenin activated |
17 | Carcinoma | 42, F | 1 | 21 | Yes | Yes | Patchy loss | 3 | β-catenin activated |
18 | Carcinoma | 5, M | 1 | 15 | Yes | Yes | Patchy loss | 2 | β-catenin activated |
19 | Carcinoma | 54, F | 1 | 6.4 | Yes | No | Loss | 3 | β-catenin activated |
20 | Carcinoma | 24, M | 1 | 19 | No | Yes | Loss | 3 | β-catenin activated |
21 | Uncertain malignant potential | 29, F | 1 | 8.5 | Yes | No | Intact | 2 | Inflammatory |
22 | Uncertain malignant potential | 75, F | 1 | 3 | No | Yes | Intact | 1 | HNF1-α inactivated |
23 | Uncertain malignant potential | 49, F | 1 | 2.2 | No | Yes | Intact | 2 | HNF1-α inactivated |
24 | Uncertain malignant potential | 45, M | 1 | 3.3 | No | Yes | Intact | 1 | HNF1-α inactivated |
25 | Uncertain malignant potential | 46, F | 4 (including 2 non-pigmented adenomas) | 13 | No | Yes | Intact | 3 | HNF1-α inactivated |
26 | Uncertain malignant potential | 49, F | 7 (including 4 non-pigmented adenomas) | Unavailable, biopsy specimen | Yes | No | Focal disruption | 2 | β-catenin activated |
27 | Uncertain malignant potential | 25, M | 2 | Unavailable, biopsy specimen | No | Yes | Intact | 2 | Inflammatory |
